期刊
JOURNAL OF HEPATOLOGY
卷 73, 期 4, 页码 794-799出版社
ELSEVIER
DOI: 10.1016/j.jhep.2020.05.029
关键词
HCV; Unusual subtypes; NS5A inhibitors; Efficacy; Hepatitis C
资金
- Medical Research Council [MR/K01532X/1, MR/P025064/1]
- Medical Research Council UK
- Oxford NIHR Biomedical Research Centre
- NIHR Senior Investigator
- NIHR Imperial College NHS Trust Biomedical Research Centre
- NIHR Research Professorship
- MRC [MR/P025064/1, MR/K01532X/1] Funding Source: UKRI
Background & Aims: The efficacy of NS5A inhibitors against several less common subtypes of hepatitis C virus (HCV) is poorly characterised. Some subtypes including 3b, 3g, 6u and 6v commonly harbour amino acid residues in NS5A that may confer resistance to direct-acting antivirals (DAAs) in other common subtypes. Data from patients also suggest that 11 and 4r with amino acid substitutions at positions 28-31 and 93 in NS5A are relatively resistant to DAA therapy. Methods: In this study, we tested the efficacy of daclatasvir, elbasvir, ledipasvir, pibrentasvir and velpatasvir against these subtypes using the SGR-JFH1 replicon backbone. Results: NS5A inhibitors showed different levels of efficacy with only pibrentasvir effective against all tested subtypes. Daclatasvir and ledipasvir were ineffective against 6u and 6v (half maximal effective concentration [EC50] values of 239-321 nM) while 3b and 3g were only susceptible to pibrentasvir. Analysis of effects of individual mutations indicated that Q30R in 11 increased the EC50 of ledipasvir by 18-fold, conferring intermediate resistance, while those of L31M and Y93H in 4r induced increases in EC50 values of 2,100- and 3,575-fold (high-level resistance). Conclusion: The high ledipasvir EC(50 )values of 11 with the Q3OR substitution, 4r L31M and 4r Y93H may explain the treatment failure in patients who were infected with these viruses and treated with ledipasvir + sofosbuvir. This study also shows the ineffectiveness of the first generation NS5A inhibitors against 6u and 6v, and confirms the inherent resistance of 3b and 3g to most NS5A inhibitors. Clinical studies to confirm in vivo sensitivity to NS5A inhibitors are urgently needed so that rational, effective treatment strategies may be developed for unusual subtypes. Lay summary: Little is known about the efficacy of NS5A inhibitors against some unusual hepatitis C virus (HCV) subtypes including 11, 3b, 3g, 4r, 6u and 6v. In this study, we manufactured HCV replicons which express the NS5A protein from the unusual HCV subtypes 11, 3b, 3g, 4r, 6u, 6v. We then tested the effect of the NS5A inhibitors daclatasvir, elbasvir, ledipasvir, pibrentasvir and velpatasvir on blocking replication, using these replicons. We show that these replicons are resistant at some level to all NS5A inhibitors other than pibrentasvir. (C) 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据